Biogen Inc. (NASDAQ:BIIB) Receives Consensus Rating of “Hold” from Analysts

Shares of Biogen Inc. (NASDAQ:BIIB) have received an average rating of “Hold” from the twenty-seven analysts that are currently covering the company, Marketbeat.com reports. Fifteen investment analysts have rated the stock with a hold rating and twelve have issued a buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $205.0385.

Several equities analysts have recently weighed in on the company. Canaccord Genuity Group lifted their price objective on Biogen from $220.00 to $230.00 and gave the company a “buy” rating in a research note on Monday, February 9th. HSBC reaffirmed a “reduce” rating and set a $143.00 price target (down from $144.00) on shares of Biogen in a research report on Wednesday, December 10th. Truist Financial increased their price objective on shares of Biogen from $190.00 to $193.00 and gave the stock a “hold” rating in a research report on Monday, February 9th. Stifel Nicolaus raised their target price on shares of Biogen from $202.00 to $214.00 and gave the company a “buy” rating in a research note on Friday, February 6th. Finally, Wedbush upped their price target on shares of Biogen from $178.00 to $187.00 and gave the stock a “neutral” rating in a research report on Monday, February 9th.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: NEJM publication: Phase 1/2a and open‑label data for zorevunersen (Stoke Therapeutics collaboration) show substantial, durable seizure reductions and cognitive/behavior gains in Dravet syndrome — a potential first disease‑modifying therapy. Data publication validates the program and supports the ongoing Phase 3 EMPEROR study (readout mid‑2027); Biogen holds ex‑US commercial rights, which raises long‑term upside if Phase 3/approvals succeed. Article Title
• Positive Sentiment: SMA program updates: Biogen will present new data on high‑dose nusinersen and Phase 1b salanersen at upcoming MDA & SMA Europe conferences — positive for the neuromuscular pipeline and near‑term investor visibility. Article Title
• Positive Sentiment: Legislative tailwind for neurology care: H.R.7336 (ALS Better Care Act) would expand Medicare coverage and payment for ALS‑related services and clinical trial incentives — could improve access/reimbursement for ALS therapies and support commercial opportunity for companies with ALS programs, including Biogen. Article Title
• Neutral Sentiment: Investor commentary: Several value/institutional investors and analyst coverage remain active (mixed buy/outperform and some reduces); some managers cite BIIB as an attractive long‑term holding, which supports demand but is not an immediate catalyst. Article Title
• Neutral Sentiment: Short‑interest reports in recent summaries show inconsistent/zero figures (NaN/0 entries) — data appear unreliable and likely have little informational value for current price movement.
• Negative Sentiment: Clinical risk & timing: zorevunersen’s promise hinges on Phase 3 EMPEROR results (mid‑2027) and safety monitoring — OLEs noted CSF protein elevations (one discontinuation). Trial, regulatory and commercialization risk—and the multi‑year timeline—are near‑term weight on the stock until confirmatory data arrive. Article Title

Insider Buying and Selling at Biogen

In other news, insider Priya Singhal sold 2,660 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the sale, the insider owned 8,043 shares in the company, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.18% of the stock is owned by insiders.

Hedge Funds Weigh In On Biogen

A number of institutional investors and hedge funds have recently bought and sold shares of BIIB. Empowered Funds LLC lifted its position in shares of Biogen by 64.9% during the first quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock worth $965,000 after purchasing an additional 2,777 shares in the last quarter. Focus Partners Wealth lifted its holdings in Biogen by 172.2% in the 1st quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock worth $1,392,000 after buying an additional 6,436 shares in the last quarter. Sivia Capital Partners LLC acquired a new position in Biogen in the 2nd quarter worth $216,000. Wealthfront Advisers LLC boosted its position in Biogen by 129.4% in the 2nd quarter. Wealthfront Advisers LLC now owns 8,684 shares of the biotechnology company’s stock valued at $1,091,000 after buying an additional 4,899 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its stake in shares of Biogen by 7.2% during the second quarter. Envestnet Asset Management Inc. now owns 56,076 shares of the biotechnology company’s stock valued at $7,043,000 after acquiring an additional 3,782 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Trading Down 1.0%

BIIB stock opened at $188.08 on Friday. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. The company has a market cap of $27.60 billion, a price-to-earnings ratio of 21.35, a PEG ratio of 1.51 and a beta of 0.15. The business has a fifty day simple moving average of $182.93 and a 200-day simple moving average of $164.75. Biogen has a 52 week low of $110.04 and a 52 week high of $202.41.

Biogen (NASDAQ:BIIB) last issued its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The firm had revenue of $2.28 billion for the quarter, compared to analysts’ expectations of $2.21 billion. During the same quarter last year, the firm earned $3.44 earnings per share. The firm’s revenue for the quarter was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, equities research analysts expect that Biogen will post 15.83 EPS for the current year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.